The Charité will participate as a clinical site to Cancer-ID and perform CTC isolation in patients with lung cancer and breast cancer with several techniques, as selected by mutual agreement between the coordination team and the Charité. Serum samples for ctDNA will also be provided. In case the clinical trial will be performed in Germany, Charité offers participation.
On the laboratory level, Charité will contribute the CTC sequencing expertise gathered from various previous programs, including the EU-IMI project OncoTrack. Several sequencing platforms have been established to be used in the program.